Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule empirique (notation de Hill) :
C23H43NNaO9P
Numéro CAS:
Poids moléculaire :
531.55
UNSPSC Code:
51191904
NACRES:
NA.25
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderdescription
1-(10Z-heptadecenoyl)-2-hydroxy-sn-glycero-3-[phospho-L-serine] (sodium salt)
assay
99% (LPS; may contain up to 15% of the 2-LPS isomer, TLC)
form
powder
packaging
pkg of 1 × 5 mg (858141P-5mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand
lipid type
cardiolipins
phospholipids
shipped in
dry ice
storage temp.
−20°C
SMILES string
O[C@](COP([O-])(OC[C@](C([O-])=O)([H])[NH3+])=O)([H])COC(CCCCCCCC/C=C\CCCCCC)=O.[Na+]
InChI
1S/C23H44NO9P.Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-22(26)31-17-20(25)18-32-34(29,30)33-19-21(24)23(27)28;/h7-8,20-21,25H,2-6,9-19,24H2,1H3,(H,27,28)(H,29,30);/q;+1/p-1/b8-7-;/t20-,21+;/m1./s1
InChI key
OALJMCAGNYARLY-XZEOLHCOSA-M
Application
17:1 Lyso PS may be used as a standard in graphitized carbon black-solid phase extraction (GCB-SPE) method for lipid extraction. It may also be used as an internal standard in the metabolomic analysis of cell and brain samples.
Biochem/physiol Actions
17:1 Lyso PS may act as an odd-chained LIPIDOMIX™quantitative mass spectrometry internal standard.
Packaging
5 mL Clear Glass Sealed Ampule (858141P-5mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
LIPIDOMIX is a trademark of Avanti Polar Lipids, LLC
Classe de stockage
11 - Combustible Solids
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Daisuke Ogasawara et al.
Nature chemical biology, 14(12), 1099-1108 (2018-11-14)
ABHD12 metabolizes bioactive lysophospholipids, including lysophosphatidylserine (lyso-PS). Deleterious mutations in human ABHD12 cause the neurological disease PHARC, and ABHD12-/- mice display PHARC-like phenotypes, including hearing loss, along with elevated brain lyso-PS and features of stimulated innate immune cell function. Here
Biyu Hou et al.
Life sciences, 245, 117352-117352 (2020-02-02)
The depot-specific differences in lipidome of visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) reflect heterogeneity of white adipose tissue (WAT), which plays a central role in its distinct response to outside stimuli. However, the detailed lipidome of depot-specific
Jordon M Inloes et al.
Biochemistry, 57(39), 5759-5767 (2018-09-18)
Deleterious mutations in the serine hydrolase DDHD domain containing 1 (DDHD1) cause the SPG28 subtype of the neurological disease hereditary spastic paraplegia (HSP), which is characterized by axonal neuropathy and gait impairments. DDHD1 has been shown to display PLA1-type phospholipase
Numéro d'article de commerce international
| Référence | GTIN |
|---|---|
| 858141P-5MG | 04061835232307 |
| 858141P-100MG | 04061835232291 |